Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-28 4:30 pm Unchanged |
2025-03-27 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 16.400% |
0 (Unchanged) |
Filing History |
| 2024-11-14 5:37 pm Sale |
2024-09-30 | 13G | Spero Therapeutics, Inc. SPRO |
Anson Funds Management LP | 3,750,450 6.900% |
-547,149 (-12.73%) |
Filing History |
| 2024-02-14 4:25 pm Purchase |
2023-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Anson Funds Management LP | 4,297,599 8.100% |
4,297,599 (New Position) |
Filing History |
| 2023-02-14 11:47 am Sale |
2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,411,520 (Position Closed) |
Filing History |
| 2023-02-14 11:16 am Sale |
2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 0 0.000% |
-3,419,435 (Position Closed) |
Filing History |
| 2023-01-20 4:08 pm Unchanged |
2022-11-14 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 17.750% |
0 (Unchanged) |
Filing History |
| 2022-11-14 5:02 pm Purchase |
2022-11-07 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 9,190,606 19.990% |
7,450,000 (+428.01%) |
Filing History |
| 2022-10-03 4:40 pm Sale |
2022-09-22 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 3,419,435 9.800% |
-1,602,101 (-31.90%) |
Filing History |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Spero Therapeutics, Inc. SPRO |
BLACKROCK INC BLK |
690,753 2.100% |
-1,108,024 (-61.60%) |
Filing History |
| 2022-03-08 5:41 pm Purchase |
2022-01-18 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 5,021,536 15.500% |
57,355 (+1.16%) |
Filing History |
| 2022-02-14 3:54 pm Purchase |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 4,964,181 15.400% |
1,031,972 (+26.24%) |
Filing History |
| 2022-02-14 1:27 pm Purchase |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BIOTECHNOLOGY VALUE FUND L P | 3,411,520 9.990% |
643,242 (+23.24%) |
Filing History |
| 2022-02-03 4:29 pm Purchase |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BLACKROCK INC BLK |
1,798,777 5.600% |
67,177 (+3.88%) |
Filing History |
| 2022-01-25 11:28 am Unchanged |
2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Atlas Venture Fund IX L.P. | 1,376,968 4.260% |
0 (Unchanged) |
Filing History |
| 2021-09-16 5:27 pm Unchanged |
2021-08-05 | 13D | Spero Therapeutics, Inc. SPRO |
GLAXOSMITHKLINE PLC | 1,740,606 5.400% |
0 (Unchanged) |
Filing History |
| 2021-07-09 4:25 pm Purchase |
2021-06-30 | 13G | Spero Therapeutics, Inc. SPRO |
PFIZER INC PFE |
2,362,348 7.370% |
2,362,348 (New Position) |
Filing History |
| 2021-02-16 5:29 pm Unchanged |
2021-02-12 | 13D | Spero Therapeutics, Inc. SPRO |
Atlas Venture Fund X L.P. | 1,031,160 3.800% |
0 (Unchanged) |
Filing History |
| 2021-02-16 4:00 pm Sale |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
Aquilo Capital Management LLC | 3,932,209 14.500% |
-564,933 (-12.56%) |
Filing History |
| 2021-02-12 8:16 pm Purchase |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
BIOTECHNOLOGY VALUE FUND L P | 2,768,278 9.990% |
739,873 (+36.48%) |
Filing History |
| 2021-02-10 4:37 pm Sale |
2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO |
GV 2015 L.P. | 889,979 3.270% |
-222,494 (-20.00%) |
Filing History |